UNLABELLED: The occurrence of malignant disease increases the risk for venous thromboembolism (VTE). Here we evaluate the risk for VTE in a large unselected cohort of patients with cancer receiving chemotherapy. METHODS: The United States IMPACT health care claims database was retrospectively analyzed to identify patients with a range of solid tumors who started chemotherapy from January 2005 through December 2008. International Classification of Diseases, 9th revision, Clinical Modification Codes were used to identify cancer location, presence of VTE 3.5 months and 12 months after starting chemotherapy, and incidence of major bleeding complications. Health care costs were assessed one year before initiation of chemotherapy and one year after initiation of chemotherapy. RESULTS: The overall incidence of VTE 3.5 months after starting chemotherapy was 7.3% (range 4.6%-11.6% across cancer locations) rising to 13.5% at 12 months (range 9.8%-21.3%). The highest VTE risk was identified in patients with pancreatic, stomach, and lung cancer. Patients in whom VTE developed had a higher risk for major bleeding at 3.5 months and at 12 months (11.0% and 19.8% vs. 3.8% and 9.6%, respectively). Health care costs were significantly higher in patients in whom VTE developed. CONCLUSION: Those undergoing chemotherapy as outpatients are at increased risk for VTE and for major bleeding complications. Thromboprophylaxis may be considered for such patients after carefully assessing the risks and benefits of treatment.
UNLABELLED: The occurrence of malignant disease increases the risk for venous thromboembolism (VTE). Here we evaluate the risk for VTE in a large unselected cohort of patients with cancer receiving chemotherapy. METHODS: The United States IMPACT health care claims database was retrospectively analyzed to identify patients with a range of solid tumors who started chemotherapy from January 2005 through December 2008. International Classification of Diseases, 9th revision, Clinical Modification Codes were used to identify cancer location, presence of VTE 3.5 months and 12 months after starting chemotherapy, and incidence of major bleeding complications. Health care costs were assessed one year before initiation of chemotherapy and one year after initiation of chemotherapy. RESULTS: The overall incidence of VTE 3.5 months after starting chemotherapy was 7.3% (range 4.6%-11.6% across cancer locations) rising to 13.5% at 12 months (range 9.8%-21.3%). The highest VTE risk was identified in patients with pancreatic, stomach, and lung cancer. Patients in whom VTE developed had a higher risk for major bleeding at 3.5 months and at 12 months (11.0% and 19.8% vs. 3.8% and 9.6%, respectively). Health care costs were significantly higher in patients in whom VTE developed. CONCLUSION: Those undergoing chemotherapy as outpatients are at increased risk for VTE and for major bleeding complications. Thromboprophylaxis may be considered for such patients after carefully assessing the risks and benefits of treatment.
Entities:
Keywords:
Cancer; Chemotherapy; Health care costs; Thromboprophylaxis; Venous thromboembolism
Authors: Paul D Stein; Afzal Beemath; Frederick A Meyers; Elias Skaf; Julia Sanchez; Ronald E Olson Journal: Am J Med Date: 2006-01 Impact factor: 4.965
Authors: Alok A Khorana; Charles W Francis; Eva Culakova; Richard I Fisher; Nicole M Kuderer; Gary H Lyman Journal: J Clin Oncol Date: 2006-01-20 Impact factor: 44.544
Authors: William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Gary H Lyman; Alok A Khorana; Anna Falanga; Daniel Clarke-Pearson; Christopher Flowers; Mohammad Jahanzeb; Ajay Kakkar; Nicole M Kuderer; Mark N Levine; Howard Liebman; David Mendelson; Gary Raskob; Mark R Somerfield; Paul Thodiyil; David Trent; Charles W Francis Journal: J Clin Oncol Date: 2007-10-29 Impact factor: 44.544
Authors: J W Blom; J P M Vanderschoot; M J Oostindiër; S Osanto; F J M van der Meer; F R Rosendaal Journal: J Thromb Haemost Date: 2006-03 Impact factor: 5.824
Authors: J Haltout; A Awada; M Paesmans; M Moreau; J Klastersky; G Machiels; M Ignatiadis; N Kotecki Journal: Support Care Cancer Date: 2019-01-04 Impact factor: 3.603
Authors: Kit Man Wong; Kathryn J Horton; Andrew L Coveler; Sunil R Hingorani; William P Harris Journal: Curr Oncol Rep Date: 2017-07 Impact factor: 5.075
Authors: Jan Beyer-Westendorf; Robert Klamroth; Stephan Kreher; Florian Langer; Axel Matzdorff; Hanno Riess Journal: Dtsch Arztebl Int Date: 2019-01-18 Impact factor: 5.594
Authors: Sunil R Hingorani; William P Harris; J Thaddeus Beck; Boris A Berdov; Stephanie A Wagner; Eduard M Pshevlotsky; Sergei A Tjulandin; Oleg A Gladkov; Randall F Holcombe; Ronald Korn; Natarajan Raghunand; Samuel Dychter; Ping Jiang; H Michael Shepard; Craig E Devoe Journal: Clin Cancer Res Date: 2016-01-26 Impact factor: 12.531